SCYNEXIS Inc

SCYNEXIS Inc operates with a market capitalization of $61.23 million and a price-to-book ratio of 1.01, indicating a valuation that closely aligns with its book value. The company holds $25.99 million in cash and equivalents, which is significantly higher than its $12.78 million in long-term debt, resulting in a debt-to-equity ratio of 0.21 and a current ratio of 3.75, both of which suggest strong liquidity. Despite this, the company reported negative operating and net income of -$9.24 million and -$14.46 million, respectively, in the latest period. The company's return on equity (ROE) is -23.93%, and its return on assets (ROA) is -13.41%, both of which are significantly below the industry median for pharmaceutical firms, indicating poor capital efficiency and profitability. Gross profit equals total revenue, suggesting no cost of goods sold, which is unusual for a pharmaceutical company and may indicate a reporting anomaly or a one-time event. SCYNEXIS generates all of its revenue from a single business segment, with no geographic diversification disclosed in the available data. This lack of diversification increases exposure to market-specific risks and regulatory changes in the jurisdictions where it operates. The company's revenue of $736,000 in the latest period is minimal, and there is no disclosed growth trajectory or guidance for the next fiscal year. Analysts have assigned a mean price target of $4.19, with a median of $4.00, suggesting a potential upside of over 400% from the current market price of $0.77. However, the absence of revenue growth and the company's continued losses raise questions about the sustainability of such price targets. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating cash flow of -$14.87 million and its reliance on cash reserves to fund operations suggest a potential liquidity risk if cash burn continues at the current rate. No dilution sources were identified in the latest filings, and the company has not issued additional shares recently. Recent events include the publication of analyst price targets and recommendations, with a mean recommendation of 1.67 (1=strong buy, 5=strong sell), indicating a generally positive sentiment among analysts. However, the company has not disclosed any major product launches, partnerships, or clinical trial updates in the latest filings or transcripts.